Hemgenix (etranacogene dezaparvovec) is now available on the European market for the treatment of severe and moderately severe haemophilia B in adults without factor IX inhibitors (autoantibodies produced by the immune system that make drugs against factor IX less effective). The recommendation for the granting of marketing authorization in EU countries is from the
Tag: EMA
Today’s EU pharmaceutical market is unsustainable, due to the fragmentation of EU players and public dependence on private interests. A recent Panel for the Future of Science and Technology (STOA) study of the EP proposes a solution involving the creation of a public European medicines infrastructure, a body that would control of the entire